Trial site
Washington University School of Medicine - Siteman Cancer Center
- 30running trials
- 20closed trials
The trials here
What the 50 trials at this site are about, from their registry records.
- Conditions
- Lung cancer13 trials
- Gastric and oesophageal cancer6 trials
- Metastatic breast cancer6 trials
- Colorectal cancer5 trials
- Head and neck cancer5 trials
- Liver and biliary tract cancer5 trials
- Pancreatic cancer5 trials
- Sarcoma5 trials
- Bladder cancer4 trials
- Diffuse large B-cell lymphoma4 trials
- Endometrial cancer4 trials
- Melanoma4 trials
- and 16 more
- Phase
- Phase 1/214 trials
- Phase 112 trials
- Phase 211 trials
- Phase 39 trials
- Phase 2/33 trials
- Status
- Recruiting17 trials
- Active, not recruiting13 trials
- Terminated12 trials
- Completed7 trials
- Withdrawn1 trial
- Lead sponsor
- Pfizer7 trials
- Vor Biopharma3 trials
- Cogent Biosciences, Inc.2 trials
- Compass Therapeutics2 trials
- Genprex, Inc.2 trials
- and 32 more
Running trials
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Recruiting
Active, not recruiting
Recruiting
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Recruiting
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Active, not recruiting
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
Recruiting
Active, not recruiting
Study of Novel Treatment Combinations in Patients With Lung Cancer
Active, not recruiting
Active, not recruiting
Recruiting
Active, not recruiting
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Active, not recruiting
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Active, not recruiting
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Active, not recruiting
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Active, not recruiting
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer4 recruiting
- Metastatic breast cancer3 recruiting
- Bladder cancer1 recruiting
- Brain metastases1 recruiting
- Childhood cancers1 recruiting
- Chronic lymphocytic leukaemia1 recruiting
- Colorectal cancer1 recruiting
- Diffuse large B-cell lymphoma1 recruiting
- Endometrial cancer1 recruiting
- Glioblastoma1 recruiting
- Kidney cancer1 recruiting
- Liver and biliary tract cancer1 recruiting
- Neuroendocrine tumours1 recruiting
- Prostate cancer1 recruiting
- Sarcoma1 recruiting
Closed trials
Terminated
Terminated
Completed
Terminated
Terminated
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Terminated
Terminated
Terminated
Recruiting
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Terminated
Completed
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
Completed
Terminated
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Recruiting
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Terminated
Completed
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Completed
Terminated
Completed
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
Terminated
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Site data: ClinicalTrials.govUpdated 18 Nov 2026